Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;18(3):129-130.
doi: 10.1038/s41571-021-00477-1.

Oncology approvals in 2020: a year of firsts in the midst of a pandemic

Laleh Amiri-Kordestani  1 , Richard Pazdur  2   3
Affiliations

Oncology approvals in 2020: a year of firsts in the midst of a pandemic

Laleh Amiri-Kordestani et al. Nat Rev Clin Oncol. 2021 Mar.

Abstract

In 2020, despite challenges related to the COVID-19 pandemic, the US FDA approved 30 new drugs and biologic agents, 45 supplemental drug and biologic applications and 1 biosimilar application in oncology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. U.S. Food and Drug Administration. FDA News Release: FDA approves first new drug under international collaboration, a treatment option for patients with HER2-positive metastatic breast cancer. fda.govhttps://www.fda.gov/news-events/press-announcements/fda-approves-first-n... (2020).
    1. de Claro RA, et al. Project Orbis: Global Collaborative Review Program. Clin. Cancer Res. 2020;26:6412–6416. doi: 10.1158/1078-0432.CCR-20-3292. - DOI - PubMed
    1. U.S. Food and Drug Administration. Oncology center of excellence guidance documents. fda.govhttps://www.fda.gov/about-fda/oncology-center-excellence/oncology-center... (2020).
    1. U.S. Food and Drug Administration. Project patient voice. fda.govhttps://www.fda.gov/about-fda/oncology-center-excellence/project-patient... (2020).
    1. Cavallo J. Efforts to broaden eligibility criteria for clinical trials seek to include more racial and ethnic minority patients: a conversation with Lola A. Fashoyin-Aje, MD, MPH. The ASCO Posthttps://ascopost.com/issues/september-25-2020/efforts-to-broaden-eligibi... (2020).

Substances